Screener
Spyre Therapeutics, Inc. SYRE Acquired in-process research and development
Acquired in-process research and development at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfIntangibleAssets.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Proceeds from maturities and sales of marketable securities | 107,748 | 71,383 |
| Purchases of marketable securities | (81,167) | (71,444) |
| Proceeds from sale of in-process research and development asset | 30,000 | — |
| Net cash provided by (used in) investing activities | 56,581 | (61) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs | 9,750 | — |
| Payment of deferred offering costs in connection with shelf registration | (171) | (93) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s acquired in-process research and development?
- Spyre Therapeutics, Inc. (SYRE) reported acquired in-process research and development of $30M in Q1 2026.
- What does acquired in-process research and development mean?
- Specifically tracks cash payments for in-process research and development assets acquired through business combinations or direct asset purchases. In the biotech industry, this represents the cost of buying early-stage drug candidates or technology platforms. It is a critical indicator of R&D pipeline investment and future growth potential.
Ask your AI about Spyre Therapeutics, Inc.'s acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude